TRANSCRIPT 🔗
WEBVTT
00:00:26.000 --> 00:00:48.000
On the Mind & Matter podcast, we learn together from the best scientists and thinkers alive today about how your mind-body reacts to what you feed it. Before starting Mind & Matter, I spent 10 years in academia doing scientific research. I got a PhD in neuroscience from Harvard University, where I focused on neuroendocrinology and the neuroscience of behavior. And before that, I specialized in molecular, developmental, and evolutionary genetics.
00:00:48.000 --> 00:01:20.000
I use my scientific background to parse and translate the information guests share on the show, and in addition to the podcast, I write long-form content and send out a free weekly newsletter at themindandmattersubstack at mindandmatter.substack.com. I also offer private, science-based health consulting. where we work one-on-one and apply the same rigorous, evidence-first approach you hear on the podcast, but personalized. We can obtain and analyze your biomarkers, work on diet and behavior strategies, review supplements and drugs that you might be taking, or anything else related to general metabolic health.
00:01:20.000 --> 00:01:42.000
So, if you'd like more tailored guidance on your personal health, head to nickjacomis.com and fill out a short form or book time with me there. A great way to support my content in all of its forms is simply to visit mindandmatter.substack.com. You'll find a link to that in the episode description, and you'll also find a link to my current affiliate partners through my support page. These are products that I use myself that relate to physical, metabolic, or mental health.
00:01:42.000 --> 00:02:15.000
For example, one product I use every day is the AquaTrue water filter, which removes heavy metals, microbes, endocrine disruptors, you name it, so that you have higher quality drinking water. All of those links for health consulting, for my affiliate partners, and the Substack page are all in the episode description. So thank you very much for listening, and don't forget to check out mindandmatter.substack.com for all of my content. Thank you very much for joining me.
00:02:16.000 --> 00:02:17.000
Thank you.
00:02:18.000 --> 00:02:22.000
Do you want to start off by telling everyone a little bit about who you are and what your background is and what your lab works on?
00:02:24.000 --> 00:02:52.000
Absolutely. So, my day job is that I'm the Dean of the School of Gerontology in the University of Southern California. That is a school that's devoted to healthy aging, longevity, and infrastructure of the aging society in the United States and abroad. In addition, I run a lab, a research lab, working on so-called mitochondrial peptide or mitochondrial microproteins.
00:02:53.000 --> 00:03:09.000
And I've been doing that for about 20 years now. Prior to that, I was at UCLA. I ran the Diabetes Research Center over there. That's where my interest in these peptides started.
00:03:10.000 --> 00:03:23.000
So, I was trained as an endocrinologist. and while I no longer see patients regularly, my focus is still on developing interventions that will improve human health.
00:03:25.000 --> 00:03:59.000
Yeah, and I think one of the things that we'll talk about today is this question of thinking about therapies from the perspective of treating diseases, fixing problems after they've started, versus promoting healthspan or health or the prevention of disease from even arising in the first place. But you've done a lot of interesting research for a number of years on mitochondrial peptides. I've talked to other people in this field, including people who came out of your lab recently. So we're going to discuss this from multiple angles and sort of build on what was on that recent episode.
00:03:59.000 --> 00:04:20.000
But let's start with some of the basics. If you sort of step back and think about your career and mitochondrial peptides and everything you've done so far, Beyond ATP, beyond energy production, what has the work in your lab said about what mitochondrial do beyond their famous textbook role in producing ATP for the cell? What else are they doing, broadly speaking?
00:04:21.000 --> 00:04:44.000
Yeah, the fifth grade mitochondria is a powerhouse of the cell. Let me say, first of all, when I went to fifth grade, which was a long time ago, I don't think we even knew that. But I think the big transition scientifically is on two levels. The first level is the recognition, like you said, that there's more to mitochondria than producing energy.
00:04:45.000 --> 00:05:26.000
And the roles of the mitochondria that have evolved over the last 20 or 30 years is, number one, regulation of cell fate. So mitochondria involved in apoptosis, or how the cells end up dying in a programmed fashion. Also, the innate immunity that people have recognized mitochondria is very critical for. And finally, the role of the mitochondria, not just as a factory, but as a communication hub, sending signals to the nucleus, to other organelles, and to other cells and other organs.
00:05:27.000 --> 00:05:59.000
So, that is conceptually the big advance in our thinking as a result of the mitochondrial peptide discovery. The other big change in our thinking as the result of this work is the expansion of the human genome. And if you Google right now how many genes there are in the human genome, You might get 20,000, sometimes it comes up with 25,000, but these are all traditional large genes that encode large proteins. Maybe you add in the so-called long non-coding RNAs.
00:06:00.000 --> 00:06:51.000
But when we cloned the first peptide that wasn't a fragment of another protein, and that was humanin 25 years ago, That really created a new class of molecules, which are these small peptides encoded from their own little genes that typically are located in places that there shouldn't be, what was previously known as junk DNA, the dark genome. Now that we recognize that in fact there are so many
Load full transcript
potential peptides, hiding in our DNA, and only 3% of our DNA were thought to contain these classical genes. The 97% that we didn't understand, you know, is where the action is gonna be in the coming years regarding research, and these peptides are a key part of that.
00:06:52.000 --> 00:07:05.000
And by understanding that we have an order of magnitude more molecules to study, to explore, and to utilize for health, I mean, that is a real revolution in science.
00:07:06.000 --> 00:07:33.000
Yeah. And when I think back on my start in science, when I started in molecular genetics, and when I started learning about the history of genetics, broadly speaking, I remember learning about, you know, when we first sequenced the human genome and going into that in the 90s, the expectation was, well, we're humans, we're so much more complex than all these other organisms, we must have hundreds of thousands or millions of genes. And then, you know, it came back that we only had tens of thousands.
00:07:34.000 --> 00:07:51.000
And one of the One of the ways people thought about that was, well, actually, even though that's surprising, we've got all of this, what was called junk DNA, that we don't know what it's doing. Some of it's regulatory. So it's not about encoding proteins. It's about deciding where these proteins get made and how much in regulation.
00:07:52.000 --> 00:08:18.000
What you're saying is there's at least one more big layer here, which is... the traditional genes that we think about in defining the genome, let's call them regular genes or big genes, there's also these sort of smaller genes that we didn't think of as genes originally. And one of the things they seem to be encoding are these small peptides or mini proteins, which are something that we're sort of just starting to appreciate the significance of.
00:08:19.000 --> 00:08:58.000
Exactly. You've nailed it. And I do also want to say something about peptides. which became sort of a general term, and people hear it all the time, you know, they're in the New York Times every day, and, you know, people talk about peptides as if it's a group of molecules that we understand, there might be 50 of them or whatever, and we know what they are. In fact, I think peptides are very complex, and I divide them into three categories. The first are molecules that are peptides, but are fragments of larger proteins. Insulin is an example.
00:08:59.000 --> 00:09:21.000
It's a fragment of pro-insulin. GLP-1 is a peptide, but it's really a component of the pro-glucagon gene. Even another very popular peptide in the hacker community called BPC-157. That is a fragment of a bacterial protein that was isolated from gastric juice.
00:09:22.000 --> 00:09:41.000
So, there's that group of peptides that are fragments. Then there's the new generation of peptides that are peptides or microproteins encoded by the small genes we call small open reading frames. And that's a really rapidly expanding group of peptides. MOTC is one of them.
00:09:41.000 --> 00:10:14.000
There's multiple others. But I think the newest category that is really going to represent what we're going to see in coming years in drug development is entirely artificial designer peptides. that with the aid of AI and other tools, we'll be able to create new peptides that don't exist in nature and design them to do specific roles, bind certain receptors or other molecules. So that's a very exciting direction in drug development.
00:10:15.000 --> 00:10:15.000
Yeah, yeah.
00:10:16.000 --> 00:10:19.000
I just think this is a super interesting field these days.
00:10:19.000 --> 00:10:34.000
Yeah. So, you know, there's much more in the genome, the nuclear genome, and the mitochondrial genome, as we'll discuss, than we once thought. Peptides are basically small proteins or mini proteins. So they're a sequence of amino acids.
00:10:35.000 --> 00:10:47.000
How small is small? And where's the cutoff between a protein and a peptide? And then can you maybe talk about what the relationship is between the size of the peptide or protein and its specificity.
00:10:50.000 --> 00:11:04.000
Right, so nobody agrees on the numbers. The current convention that's being proposed is to define peptides as less than 100 amino acids. That's quite large. Other people used to say 50.
00:11:04.000 --> 00:11:25.000
I think that 100 is probably going to be the dominating number. When you go down to the lowest cutoff, we have peptides that are three amino acid long, including several. One that's recently been approved by the FDA was originally known as SS31. That's a tripeptide.
00:11:25.000 --> 00:11:51.000
There's several other naturally occurring tripeptides and also fragments that are being designed that are tripeptides. SS31, by the way, is really an artificially designed peptide that was discovered to have important biological activities. So, I think, I guess, one amino acid is an amino acid. Two, I guess, conceptually, is a peptide, and three are definitely legit peptides.
00:11:51.000 --> 00:12:05.000
So we have examples of peptides that are only three amino acids long. They're very short. So they can get down to at least three peptides, even though you could imagine maybe dipeptides. And they go up to dozens and dozens.
00:12:06.000 --> 00:12:08.000
And eventually, we just start calling them proteins at some point.
00:12:09.000 --> 00:12:10.000
Exactly.
00:12:11.000 --> 00:12:49.000
And so I would imagine that, you know, if I imagine a tripeptide, that's just three amino acids, and I imagine something that's 50 or 100, as the length of a polypeptide increases, and we add more and more amino acids, you go from just having a chain of amino acids to something that can be folded on itself and have a secondary and tertiary structure. And so I would imagine there's a relationship between the size of the polypeptide, the size of the mini protein or protein that you are working with, and its specificity in terms of its overall
structure and the types of interactions it could have with DNA, with other proteins and so forth.
00:12:52.000 --> 00:13:29.000
Right, so the word specificity, I'm not sure that really applies necessarily. You're absolutely right that the larger a chain of amino acid is, whether it's a large peptide or a protein, the more defined its structure. And one of the things that we've been struggling with in the peptide research community is the fact that when you just look at them, let's say Moxie, 16 amino acids and several other peptides of similar size, they don't really have a structure when they're in solution. So, they're thought to be just floating chains of amino acids.
00:13:29.000 --> 00:14:13.000
but when they actually are in a physiological setting and they interact with their partners, so whether it's a GLP-1 that interacts with its receptor, it's a very specific binding of a particular pocket in the receptor that then activates signal transduction. So, these peptides find a way to form a structure. Same thing with MOTC. When it identifies its binding partner, which in this case is a molecule called CK2, it fits exactly into a particular pocket with one or two critical amino acids from each side being involved in this interaction.
00:14:14.000 --> 00:15:08.000
So I think that what we've found is that there is a general movement in the drug development community that when you develop, when you discover a peptide, say GLP-1, and you realize that it has important biological effect and it's gonna be a successful drug, the first thing people tell you is try to find a small molecule that mimics the action of this peptide. And for GLP-1, that was recently done when Eli Lilly developed a small molecule that activates the GLP-1 receptor so it can be taken orally, which is different than the oral version of Ozempic that Novo Nordisk creates. So that's because they could distill the structure of the business end of GLP-1 into a small molecule that fits exactly in the binding packet of the receptor for GLP-1.
00:15:08.000 --> 00:15:14.000
Got it. So it's a completely different molecule, but it was designed based on knowing the structure and the interactions of peptide.
00:15:14.000 --> 00:15:16.000
Both sides of the interaction.
00:15:17.000 --> 00:15:17.000
Yeah.
00:15:17.000 --> 00:15:56.000
From peptides that we work on, sometimes we identify the fact that A, they seem to have more than one binding partner. So, the first peptide we discovered was discovered by three different groups in 2001. and that was called humanin. And since then, people have identified at least three different binding partners for humanin, each one completely different, each one mediates totally different effects, sometimes in a coordinated way.
00:15:57.000 --> 00:16:04.000
and we realize there's no way we can design a single small molecule that will have all the functions of that peptide.
00:16:04.000 --> 00:16:13.000
Yeah, so you can design a small molecule drug that might
mimic the interaction with one binding partner, but not all of them if there are many.
00:16:14.000 --> 00:16:51.000
Exactly. So I think that, and it will remain to be determined if this new orally available small molecule version of GLP-1 is really going to have the same biological effect as the natural molecule. I think it's an experiment that we're doing right now at the community in health. The concept that you need small molecules to create successful products that people will be willing to take for their health, I think that has been challenged over the last three or four years, much to my surprise.
00:16:52.000 --> 00:17:26.000
there appear to be hundreds of thousands of people who have no hesitation injecting themselves with peptides. And I think that demonstrates that it's no longer a critical part of drug development to create orally available versions of these products. So, that allows the peptide research community to really focus on other aspects of the modifications of these peptides to make them active products that have benefits.
00:17:26.000 --> 00:17:51.000
Yeah, yeah. And I think one of the things you're talking about here is, you know, by nature, if you swallow most of these peptides, with certain exceptions, they're going to be degraded by your stomach and GI tract. So they're not orally active, in contrast to small molecule drugs. So there's probably a history here where It was just sort of presumed, well, if you have to inject something to get around that issue, like a peptide, people just aren't going to want to do this.
00:17:52.000 --> 00:18:04.000
So let's maybe not work on it or not focus on it. Add to that the fact that a lot of these peptides that you and others have discovered and worked on were effectively invisible. We kind of didn't know they were there. They're encoded by smaller genes until recently.
00:18:05.000 --> 00:18:16.000
That probably has a lot to do with the history here and why peptides are sort of seeing a resurgence in popularity, both on the research side and among people who apparently are willing to inject therapeutics.
00:18:18.000 --> 00:19:00.000
Exactly. You know, I think that, and I'm sure you're aware, The FDA convened a committee called PCAC that reviewed six, seven peptides, six of which this committee recommended for legal compounding that will probably begin in a few months. and that completely changes the opportunity to do additional development, additional clinical research, and I think will also encourage classical pharma drug companies to invest in next-generation peptides that will end up as approved drugs. It's a very exciting time to be in this field.
00:19:01.000 --> 00:19:15.000
And I think that we can now explore the biology, the physiology, and the clinical benefits and, of course, the concerns related to these peptides in a much more organized fashion.
00:19:15.000 --> 00:19:26.000
Yeah. So let's talk about some of the endogenous peptides and some of the peptides you've worked on. You mentioned one briefly called humanin. So talk a little bit about that one.
00:19:26.000 --> 00:19:34.000
What was the discovery process like there? When did that happen? And what did we start to learn about this peptide after you figured out it was there?
00:19:35.000 --> 00:19:52.000
Right. So humanin was discovered simultaneously by three different groups. My lab actually cloned it when we were back in Philadelphia in the late 90s. And to be honest, when I saw it for the first time, I said, this cannot be right.
00:19:53.000 --> 00:20:15.000
It's obviously an artifact. And I told my team, go back and figure out what's really happening here. And the story was that we were working, so I started my career working on growth hormone and IGF-1. and growth hormone-related peptides, like growth hormone-releasing hormone and other growth hormone secretogogues, some of which, by the way, are now part of the peptide universe.
00:20:17.000 --> 00:21:07.000
And we were very interested in the biology of how growth hormone works, which is A, to stimulate something called IGF-1, which promotes many of the effects of growth hormone, but also other activities, including making something called IGF-BP3, which binds to IGF and regulates its activities, and also, we thought, is involved in some processes related to diabetes and Alzheimer's disease. And using various approaches, we recognized that IGF-PP3 acts beyond binding IGF-1. because when we eliminate the IGF system form models or cells, we still get a biological effect of IGF-PP3.
00:21:07.000 --> 00:21:47.000
So we told ourselves it must interact with another protein to do that, and we utilized a technique called the yeast-to-hybrid system. which is really a fishing expedition. You take a molecule, that's the bait, in this case it was IGFPP3, you transfect it into a yeast cell, and you also transfect a library of a cDNA, which is really a universe of molecules, proteins, that you can put into the same yeast. And if your protein and one of the proteins in the library interacts, It allows the yeast to survive.
00:21:48.000 --> 00:21:54.000
And then you can pinpoint what proteins bind to your protein of interest. Yeah.
00:21:54.000 --> 00:21:59.000
It's like you're fishing. You have a protein. Yeah. You want to see what sticks to this protein.
00:21:59.000 --> 00:22:04.000
Is there anything out there? And you can put it into a yeast cell and something will stick or not. And then you can see it.
00:22:05.000 --> 00:22:26.000
Exactly. And, you know, it's a complicated technique. And, you know, we turned out that IGF-B3 binds more than IGF. We published a couple of solid observations with biological significance, including a molecule, a nuclear receptor called RXR, and another receptor known as the transferrin receptor.
00:22:27.000 --> 00:23:01.000
But we kept cloning a piece of DNA or RNA encoded from it that comes from a region of the mitochondrial DNA known as the 16S ribosomal RNA, which is a
structural RNA involved in translating proteins into mitochondria. And that was never supposed to encode an actual protein. It was supposed to encode a structural RNA. So I was like telling myself, how could this be something isn't quite right.
00:23:01.000 --> 00:23:32.000
What are we looking at here? And then at the same time, two other groups were using completely different visions to identify new peptides, new proteins. One was a gentleman named John Reed in the Burnham Institute, who was a very famous Bax scientist, cell death scientist. And he also believed that Bax and similar molecules have new protein partners that regulate the process of apoptosis.
00:23:32.000 --> 00:24:11.000
and he pulled out humanin using a yeast two hybrid system with Bax as bait. And he didn't know what to do with it for a couple of years. And then the gentleman who ended up naming humanin was a Japanese scientist called Iku Nishimoto, working in Keio University. And he was an Alzheimer's researcher, and he believed that there would be endogenous proteins that protect brain cells from dying in response to amyloid beta, which is the classic business end of the Alzheimer's process.
00:24:12.000 --> 00:24:53.000
And he used another screening tool, which was a death trap, where you throw amyloid beta on cells, neuronal cells, they all die, then you transfect the library into these cells prior to that, and if some cells survive, it's because they express a protein that protects them. and he cloned the same thing, the human region from the mitochondrial DNA. And while all of us were beginning to consider the possibility of a small open reading frame that encodes a protein peptide, he actually, you know, said, this is what's happening here. He really innovated the field by recognizing this new phenomenon.
00:24:54.000 --> 00:25:20.000
and ended up publishing the first paper on humanin and getting the right to name it. And immediately, I contacted him and his team, and we started working together. And the other folks at the Burnham Institute also jumped in, and we recognized that we got a new phenomena here. Small peptides encoded by new open reading frames that weren't previously recognized as real genes.
00:25:20.000 --> 00:25:31.000
Yeah. So you find a gene, effectively, that didn't really look like a normal gene. It's in the mitochondrial genome, not the nuclear genome. And you're working in yeast, it sounds like.
00:25:32.000 --> 00:25:34.000
Why is the name of this thing humanin?
00:25:38.000 --> 00:25:54.000
who, you know, who unfortunately passed away from cancer a few years ago. He had this vision that when people develop Alzheimer's disease, they lose their humanity. So, Humanin was supposed to restore their humanity. Nice name.
00:25:54.000 --> 00:26:08.000
I liked it. I ended up naming a bunch of other peptides completely differently. We can talk about that. But, of course, the yeast-to-hybrid system was a tool to identify this molecule.
00:26:09.000 --> 00:26:48.000
But since then, humanin has been the most studied microprotein. There are, I think, about 500 papers now published on humanin from, you know, 50 and more different laboratories around the world. All the work being done today is either in human cells or mammalian models like mice, and there's some remarkable activities for humanin, including promoting longevity, improving heart disease, really effectively preventing Alzheimer's, cardiovascular benefits. Really, it's a very potent molecule with significant effects.
00:26:49.000 --> 00:27:40.000
And I think you might be aware that about 12 years ago, I started a biotech company, which was called Cobar, together with my college roommate, Nir Barzilai, who is also a big longevity researcher. And we recognized the potential of human in the company, Cobar, really started out hoping to develop human analogs as drugs. We ended up changing course and developing MOXIE analogs, but we believe that humanin will have substantial benefits as an intervention. That didn't happen, and I think it's a shame because I think there's a lot of potential for humanin We have several patents of humanin altogether.
00:27:40.000 --> 00:28:01.000
There are more than 60 patents related to humanin filed that you can see online. Most of them are expired. So I think there's less interest in the pharma community to work on humanin because the IP landscape is problematic for them. But I believe it does have potential to become a therapeutic.
00:28:03.000 --> 00:28:14.000
There were issues related to human in terms of formulation and stability that really sent us into a different direction about 10 years ago.
00:28:14.000 --> 00:28:26.000
Yeah. Well, just thinking about the biology for a moment, can you give us a basic sense of the structure and function of human and how big is this thing and what does it look like? And what are some of the salient findings that have been out there in terms of what it's doing for cells?
00:28:27.000 --> 00:28:43.000
Right, so it's a 24-amino acid. It's a naturally occurring peptide. It's reasonably well conserved. There is a version in fish There isn't quite aversion in flies.
00:28:44.000 --> 00:29:10.000
Maybe there is something in worms, maybe not. But all mammals have human in and it's very well conserved. Interestingly, there's a phenomena called numpt. I don't know if you've heard that word, Nick, but over the course of evolution, fragments of mitochondrial DNA, large fragments of mitochondrial DNA, got incorporated into the nuclear DNA.
00:29:10.000 --> 00:29:31.000
Now there's nuclear mitochondrial DNA transfer. Why that happens is not clear, but it happened multiple times. So what that created are analogs of humanin, which is a mitochondrial microprotein, found a nucleogenome. And there's over 20 versions of humanin in the nucleogenome.
00:29:32.000 --> 00:29:35.000
So it probably got duplicated and expanded multiple times.
00:29:35.000 --> 00:29:49.000
Exactly. So I don't know
about expanded. a fragment came out of the mitochondria of DNA gets incorporated in the human, in the nuclear DNA. And then over evolution, it becomes degenerate.
00:29:49.000 --> 00:30:06.000
So none of those versions of human in the nuclear DNA are exactly identical to human. Yeah, yeah. But some of them do exist. And we identified using mass spec, mass spec approaches that they're found in tissues.
00:30:07.000 --> 00:30:30.000
and there are some methylation sites next to some of them that seem to regulate their biology. So, humanin seems to be a very important fundamental molecule, and it's not just, I think, a coincidence that it was the first one discovered and discovered simultaneously by several groups. It is a very important functionally. There are several receptors for humanin.
00:30:31.000 --> 00:31:14.000
There's one which is a trimeric receptor, similar to the IL-6 family of receptors, that probably regulates a lot of the effects on the neuronal system and the Alzheimer's prevention effects of humanins. There's another set of receptors called formal peptide-related receptors, or FPRL receptors, that HumanIN also binds. HumanIN interacts with IgF-BP3 and modulates both the growth hormone-IgF axis, and IgF-BP3 carries HumanIN into circulation. There might be additional proteins that HumanIN interacts with.
00:31:15.000 --> 00:32:09.000
With all these different pathways, human inregulates multiple signaling pathways in cells, including classical pathways like AKT, as well as ERK pathways and others, and has really interesting profound effects in multiple systems, both in vivo and in vitro. I think the most exciting things in the human field for me was that about four or five, three or four years ago, again, working with my colleague Nir Barzilai, who has put together a cohort of centenarians, and 500 or so centenarians, all of them happen to be Ashkenazi Jews. And he's been studying this population for 20 years now trying to identify genetic explanations to their exceptional longevity.
00:32:10.000 --> 00:32:47.000
And together we embarked on sequencing the mitochondrial genome in centenarians to identify maybe there's something there that helps them become so old, healthily. We discovered that there's a variant, I don't want to call it a mutation, but it's a naturally occurring variant of humanin, which now we call P3S humanin. It's a one amino acid difference. it's what we call a Jewish specific version of human in and found 1% of Ashkenazi Jews in general.
00:32:47.000 --> 00:33:08.000
But when we look at centenarians, its frequency is 20 times higher. So it really is enriched in centenarians. And Those people who carry this version of humanin are completely protected, even at age 100, of getting any kind of cognitive decline, which is remarkable.
00:33:08.000 --> 00:33:15.000
So none of them that have that variant show signs of Alzheimer's or anything like that, even at 100 years of age or older.
00:33:16.000 --> 00:33:44.000
Yes. And even more exciting is the fact that I think most people are familiar with ApoE4, which is sort of the big genetic risk factor for Alzheimer's disease. And when people have ApoE4, they're much more likely, A, to die younger, but of course to develop Alzheimer's disease. And by age 70, people with APOE4 often begin to experience the results of having that gene.
00:33:45.000 --> 00:34:41.000
By age 80 and 90, you'd expect all of them to have some problem. Lo and behold, we found that among 100-year-olds, There are people who carry the APOE4 gene with no evidence of any biological issues, and almost all of them also carry the P3S human inversion, which neutralizes the APOE4. We had a very nice paper a couple years ago showing that there is a direct physical interaction that apoE4 and humanin are related both genetically, there's a genetic kind of crosstalk, physical interaction, and biological relevance related to the protective effects. And, you know, there's a whole science related to APOE4 resilience, because people recognize that some people do make it with APOE4.
00:34:42.000 --> 00:34:58.000
And now, this is one example of a direct binding of human into APOE4 to negate its negative effects. And, you know, that's another possibility to explore human as a potential intervention. So, it's a fascinating molecule.
00:34:58.000 --> 00:35:09.000
Yeah. So APOE4, it's connection to Alzheimer's. People with APOE4, they're predisposed to Alzheimer's. They're more likely to get it at all.
00:35:09.000 --> 00:35:40.000
They're more likely to get it more severely earlier and die earlier. This subset of just Ashkenazi Jews has this variant of humanin, a mitochondrial peptide that is associated with their exceptional longevity and appears to prevent the development of Alzheimer's even in APOE4 individuals within that subpopulation. So there's some kind of connection here between neurodegeneration and humanin and what it's doing. If we step back a little, what else do we know about its basic function in the cell?
00:35:40.000 --> 00:35:42.000
Does this connection make sense to you?
00:35:45.000 --> 00:36:54.000
You know, that observation came after 20 years of human research, where the focus was on human and binds one of two receptors, there's signaling that's important for cell function, including in neuronal cells in the Alzheimer's setting. And I should point out that we show that mice that are engineered to express APOE4 and therefore develop brain dysfunction, somewhat similar to Alzheimer's disease in humans, you can ameliorate that by injecting these mice with this version of humanin called P3S-humanin. But prior to that, multiple groups have shown that just taking classical Alzheimer's mice models that triple transgenic and 5x fad and such models of Alzheimer's disease that don't involve the APOE4, even it still has very profound effects on delaying the progression of Alzheimer's-like symptoms. So, it seems to have multiple ways of preventing
dementia, the client.
00:36:54.000 --> 00:37:47.000
And I should point out that You know, a lot of people are working in this field, particularly in the human field, are biologists, cell biologists, physiologists, doing important work. We introduced a new angle to this whole peptide research field by incorporating genetics. and by that I mean we started doing these versions of GWAS, and I think, Nick, your audience is familiar with the term, genome-wide association studies, where you take large populations of people, all of which had genotyping or gene sequencing performed, then you look at a subpopulation with a certain condition, whatever disease you like, and compare them to another type of population that's otherwise similar.
00:37:48.000 --> 00:38:39.000
And then you see if there's any particular genetic variant that's represented in one of those groups that can be linked to the condition or disease you're studying. And we looked, so we've been employing this approach using mitochondrial genetics for a decade now, using multiple cohorts. Our favorite, which is based in our school, led by a woman called Aileen Crimmins, is called the Health and Retirement Study. 30,000 people followed now for 40 years, and some of them have passed, and we have DNA and RNA information about them, and that's our big playing field, but we've also worked on the so-called UK Biobank, in other cohorts, like the MESA cohort.
00:38:41.000 --> 00:39:25.000
Many of them are in my area of interest, which is diabetes, but also in Alzheimer's disease, we also looked at other cohorts. And in all those cohorts, we employed a version of GWAS that we call MIWAS, which is mitochondrial-wide association study. The reason for that is because, you know, When GWAS became popular, and it was transformative in science, the folks who worked on GWAS, mostly statisticians who applied their skills to biology, decided to ignore the mitochondria. leaving all the mitochondrial information on the table, which we gladly took over.
00:39:25.000 --> 00:39:53.000
The reason for that was that mitochondrial DNA is really interesting, Nick, in the sense that you only get it from your mother, as opposed to all the other genes that you get from both parents. These nuclear genes undergo recombination, and you also have two sets of them, one for your dad and one for your mom, and you can have multiple combinations of these genes. not so for mitochondrial DNA. You only get it from your mom.
00:39:53.000 --> 00:40:25.000
And while there are many mitochondria in every cell and many chromosome, mitochondrial chromosome in each mitochondria, but they're all the same, theoretically. There's no double versions, no recombination. So, each ethnicity has very specific variations in the nomadic country of DNA. I'll give you an example of P3S in Jews, but we just published a paper last week, Nick, on a new peptide called Mench, It's a fascinating peptide.
00:40:26.000 --> 00:41:07.000
And we were looking for variations in mitochondrial DNA associated with diabetes. And we looked at the health and retirement study, and we found something. And then we subdivided our analysis by ethnicity. And lo and behold, this variant, which predisposes people to diabetes and obesity, in an open reading frame encoding a peptide that we named mensch, that variant is only found in really Mexican and Mexican-Americans, or as my colleague Kelvin Yen, who discovered this, likes to say people native to the Americas.
00:41:07.000 --> 00:41:14.000
Right. Indigenous American populations, which includes a large percentage of people that are Mexican or Latin American.
00:41:14.000 --> 00:41:32.000
Right. So really, when we say native to the American, the immediate thought is we're talking about Native Americans, who, of course, by the way, also carry this variant. But they're a very small community, relatively speaking. There are many, many millions of Mexicans and Mexican-Americans who carry this gene.
00:41:33.000 --> 00:42:05.000
But, of course, so do Native Americans. What this happens to be is it's a classic thrifty gene. And by that, people who coined this term many years ago mean that When you live in an environment where there's very limited nutrients and you really need to hold on to every calorie to survive, if you have a gene that burns a lot of calories, that's not a very efficient way to manage nutrients.
00:42:05.000 --> 00:42:37.000
So, up until a hundred years ago, evolution favored thrifty genes. And the mutation that we discovered in mensch, and mensch helps you burn fat. So, when you have very limited calories, when people migrated from Asia through Alaska into North America and into South America, the mutation that inactivates mensch may have been beneficial, right? Because it helped you hold on to calories.
00:42:38.000 --> 00:43:14.000
Now, when everybody has a pickup truck and there's a McDonald's in every corner, it's no longer a beneficial gene to have the mutation in mensch. So, we discovered this new variant in a new open reading frame encoding a new peptide that is associated with much higher risk of diabetes and obesity. And 20% of Mexican and Mexican-Americans carry that. Certain Indian communities, like the Pima Indians, it's over 50%.
00:43:14.000 --> 00:43:47.000
It clearly correlates with diabetes risk. And that SNP is only found in that population. But then we take this peptide, inject it into mice or treat cells with it, and it has clear evidence that it reduces weight, it improves blood sugar, and works in many ways like, I don't know, GLP-1, perhaps, although quite differently. So, that's an example of how we utilize genetics to discover new microproteins.
00:43:47.000 --> 00:44:40.000
By focusing first on the disease. We've done it a different time with a peptide we call Schmooze, where my colleague, Brendan Miller, who is now working at the Salk Institute, was interested in Alzheimer's disease and believed that beyond humanin there might
be other mitochondrial microproteins that are involved with Alzheimer's. And he conducted this genetic screen called MIWAS on a bunch of cohorts that are focused on Alzheimer's disease. And he cloned this SNP, he cloned this peptide called schmooze, that he named schmooze, which is also neuroprotective, has the mutation and activates the protein, and it, when administered to mouse model for Alzheimer's disease, it improves the outcome.
00:44:41.000 --> 00:44:53.000
And we've done it another time with MOTC. Now, when we discovered MOTC about 15 years ago, and my colleague David Lee was a postdoc in my lab, worked on it, and
00:44:55.000 --> 00:44:58.000
he basically guessed what it's going to do.
00:44:59.000 --> 00:45:22.000
He threw it here, he threw it there, tried in this model, tried in that model, he noted this has metabolic activity, did some more stuff, really honed in on exactly what's going on, showed that you administer it to mice, you get weight loss and improved metabolism. Great story. but no origin story. And I love origin stories.
00:45:23.000 --> 00:46:08.000
So later we went back, and in collaboration with some folks in Japan, including a gentleman called Hirokuma Gai, who spent some time in my lab and is now back in Japan, we looked at the Japanese cohort. that was focused on aging. And we looked for variants in this MIWAS approach that are associated with muscle mass, because Hiro is an exercise physiologist originally. Lo and behold, we identified a mutation in the MOTC gene that renders it completely inactive, which is found in 8% of Japanese people.
00:46:09.000 --> 00:46:35.000
These 8% of people in Japan have a high risk of developing diabetes and also have low muscle mass or sarcopenia. That makes complete sense in the context of what we now believe MOTC could be useful for, which is a combination of prevention of metabolic dysfunction, maintaining weight, and most importantly, maintaining muscle mass.
00:46:36.000 --> 00:46:50.000
Yeah. And if people are interested in MOTC more, I'm sure we'll talk about it here. But as you may or may not know, I just did a discussion with Dr. Li where we did a lot of discussion of MOTC. So I would encourage people to listen to that one in conjunction with this one.
00:46:50.000 --> 00:47:25.000
But Professor Cohen, one of the things I want to emphasize here for people that I think is really important comes from your genetics perspective that you're bringing on all of this, because people often overlook this, even scientists oftentimes, which is for everything that you've talked about so far, all of these mitochondrial peptides, MOTC, MENSH, SMUS, et cetera, there's natural variation in all of them. We all have different variants and those can be substantial in the sense that they protect or predispose us to disease. They help our metabolism in certain ways.
00:47:26.000 --> 00:48:02.000
or they tell us something about our ancestry and our origins. What's important about this from a health perspective, in my view, is when you talked about that variant of mensch, I believe, that's found in certain indigenous American populations, If you connect that back to where people migrated from and where populations came from, there's this idea that, well, if these are thrifty genes, they may have helped in an ancestral environment, but they predispose us to disease in the environment of today, which is an environment of abundance. And anytime we think about ancestral environments, we also have to ask, whose ancestors?
00:48:02.000 --> 00:48:17.000
Which part of the world? Which environments? What I'm sort of queuing up here for our later discussion is when we start talking about the exact the use of exogenous peptides among people today, we also have to ask, which variants are they taking? And I think that's interesting.
00:48:18.000 --> 00:48:35.000
But going back to the MOTC stuff, I talked a lot with David about MOTC and animals and some of the work that you had done with him on the preclinical side. What do we know about MOTC in humans today? Have you done any clinical work on it? Do we know how it affects human beings?
00:48:36.000 --> 00:49:06.000
Yes, so again, to be honest, when we formed this company, Cobar, over a decade ago, We relied on the observation that David Lee and I made in mice, and there were A, that it prevented weight gain in a high-fat diet context, and B, that it really potently, completely prevented the development of fatty liver in these mice that, like humans, develop it when you give them a bad diet.
00:49:06.000 --> 00:49:07.000
Yeah, it was striking.
00:49:08.000 --> 00:49:57.000
And it was striking in mice. So we formed this company, we raised enough money to initially looked at human and unsuccessfully, we transitioned to MOTC, we did some analoging of MOTC, and came up with a variant that was one amino acid different, that just extended the half-life somewhat, but otherwise was basically MOTC. We took it through IND-enabling studies and toxicity studies of multiple species, sailed right through. We conducted phase 1A clinical trials in 60-some people with very high doses of, you know, 200 milligrams per person with no evidence of side effects whatsoever.
00:49:57.000 --> 00:50:37.000
Then we conducted a phase 1B clinical trial on 23 people that were randomized to placebo or the 4211 MOTC analog to dose of 20 milligrams per day for four weeks. And these were all obese people with fatty liver, pre-diabetics, if you will. And we've shown that the four weeks of MOTC, daily MOTC injections, resulted in some weight loss, improvements in blood sugar and improvements in liver enzymes that are representative of the fatty liver status.
00:50:37.000 --> 00:50:39.000
So, that was once daily injections for four weeks.
00:50:40.000 --> 00:50:57.000
Correct. So, this was great on one level. It really proved that we had no drug-related side effects. You know, the dose, semi-arbitrary, as sometimes that is the way it
goes in drug development.
00:50:57.000 --> 00:51:36.000
You have to pick a dose, It wasn't a bad dose in any sense of the word. People who are taking MOTC in the biohacking community often use lower doses, and that may emerge as the right approach. But what happened in 2020 when we were conducting these studies is that Ozempic came out and exploded. And we realized that our modest improvement in weight and blood sugar could match the incredible benefits of potent GLP-1s.
00:51:37.000 --> 00:52:46.000
And our investors decided to not continue developing MOTC because it appeared not to offer greater benefits than GLP-1. What we didn't understand at the time, we started really getting that about six or seven years ago, is that moxie sure has these metabolic effects on weight, but its main action is on muscle, and the key benefits of MOXIE are in maintaining muscle mass, in preventing sarcopenia, as noted by the genetic variant, multiple animal models, and most of this work has been done by Hirokuma Gai, whom I've mentioned, who really is a muscle biologist and an exercise physiologist, and he showed in multiple studies that you can take mice, For example, mice subjected to cast immobilization, which you basically, like anybody who broke a leg or an arm, you get put in a cast for a couple months to let the bone heal.
00:52:47.000 --> 00:53:03.000
When you do that, you get major atrophy of the muscles in that limb, which can be a problem. Hero treated mice that we put a cast on with MOTC and completely protected them from muscle mass.
00:53:03.000 --> 00:53:17.000
So you put a little cast on mice, and normally the muscle would atrophy after some time, as you'd expect. But if you did that while giving them MOTC, probably once daily, it prevented that muscle atrophy. Exactly. Wow.
00:53:19.000 --> 00:53:20.000
A short term, a few weeks.
00:53:21.000 --> 00:53:35.000
Wow. So we see that in animals. You've done some of those small initial trials, which didn't proceed because of the GLP-1s coming to the forefront of everyone's minds. What about endogenous MOTC in human beings?
00:53:35.000 --> 00:53:46.000
It's being called an exercise memetic, and it's supposedly induced by physical activity. What have people seen with regard to how endogenous MOTC changes with physical activity in human beings?
00:53:46.000 --> 00:54:22.000
So the exercise connection. That is now where our focus is, and this is where we think there's potential utility of MOTC as an emerging therapeutic. And the word exercise mimetic is something we came up with right from the start. because that's a great concept to have, but it's also exercise-induced, so the endogenous levels, so we also, under the strength of my lab, is that we develop assays for all these peptides, including humanin, MOTC, and others.
00:54:23.000 --> 00:55:00.000
So, when we measure MOTC levels in people, in humans, as well as mice, before and after exercise, we see a dramatic increase in MOTC within minutes, but also in people who are trained versus sedentary, we see much higher levels in the trained people. So, it's exercise-mimetic, exercise-induced, but also exercise-enhancing. So, this is David Lee's work. you know, I was involved with that, but really with him and his postdoc, Joe Reynolds, or his students.
00:55:01.000 --> 00:55:55.000
And what we've seen is that if you take mice, particularly old mice, and I'm sure David talked about it in the podcast we did with him, it enhances the exercise capacity, it allows mice to run significantly longer through And we've done other studies that are not published yet that shows that there's clear improvement in strength in response to administering MOTC. The whole thinking on MOTC shifted for us from the weight metabolism regulation that it is involved in to the muscle biology aspect, which is the key effect. And now when we think about how could we harness that with MOTC to advance it into clinical development, we think of those situations where you have muscle loss.
00:55:56.000 --> 00:56:29.000
So I gave castor mobilization as an example because it's an acute, quick way to show the effect. But the biggest issues with muscle in today's society is what we call sarcopenia of aging. You're a young guy, Nick, but I'm, you know, well into my 60s, and I can tell you, you lose muscle mass when you age, even if you try to exercise, which I do, but to keep your muscle mass, you have to exercise and lift weight many hours a day, and frankly, no one can do that.
00:56:30.000 --> 00:56:55.000
So, the chase, the race for new drugs that promote muscle growth, that's the biggest thing in drug development today. If you think about what was the biggest problem we were facing 15 years ago, it was obesity. It was the main cause for so much of what ails Western society. We conquered obesity, Nick.
00:56:55.000 --> 00:57:04.000
GLP-1 did the job. One out of eight Americans is on it now. It's a $60 billion industry. It's effective.
00:57:04.000 --> 00:57:37.000
It reduces mortality. It's an incredibly successful drug. Our new problem as a society is sarcopenia, and particularly in the GLP-1 context, as great a drug as it is, The biggest issue with GLP-1 is that one-third of the weight you lose is muscle. And even though the overall benefits are clear, that muscle loss might come back to haunt us later.
00:57:38.000 --> 00:57:45.000
Of course, you can tell people you should lift weight every day for a couple hours and that will slow it down. Most people don't do it.
00:57:45.000 --> 00:57:54.000
Yeah, yeah. And for those, I mean, for those who don't lift weights, gaining one or five pounds of muscle is a lot of focused work, believe me.
00:57:55.000 --> 00:58:20.000
Right? So, I think that utility of agents like Mod-C in the context of companion drugs for GLP-1 is very exciting in the context of acute events like gastrointubation or post-surgery. where you lose muscle mass, that's compelling. And as a treatment for sarcopenia
of aging is also a very exciting direction.
00:58:21.000 --> 00:59:13.000
Now, clearly there are people out there in the biohacking community who take illegal moxie that's labeled for research use only because they think it will enhance their exercise capacity. We don't have data for that in humans. But I think there's a legitimate important medical use for MOTC and MOTC analogs in the future for maintaining muscle mass, and secondarily, bone density. So, there's a number of papers, not from our group, but from other groups, showing that in models of osteoporosis, MOTC ameliorate that prevents that, and the osteoporosis, which is a byproduct of aging as well as muscle loss, can also be protected by MOTC.
00:59:14.000 --> 00:59:37.000
And so there's all these emerging new roles for MOTC that I think still make it a viable candidate for drug development. And now that it's going to be approved as a compounded peptide, We hope to see what are going to be the results that people will see and perhaps do some more clinical studies to demonstrate specific effects.
00:59:37.000 --> 00:59:47.000
Yeah. So it sounds like endogenous MOTC is induced under states, particular states. Exercise will do it. Other forms of metabolic stress will do it.
00:59:48.000 --> 01:00:04.000
So there's a pattern of induction. It's not necessarily cranked up all of the time. In the studies that have been done in animals and humans, there is some kind of administration protocol. Some amount of MOTC is given either once daily or intermittently.
01:00:04.000 --> 01:00:21.000
Let's say someone out there was really excited about MOTC. They're listening to your podcast here and they're saying, wow. prevent sarcopenia, other metabolic benefits, might enhance my exercise, I'm going to start injecting MOTC every single day. It sounds like there's only upside.
01:00:21.000 --> 01:00:31.000
Based on what we know about the basic biology and the effects on cells and metabolism, any potential downside to taking too much MOTC for too long for an animal or a human?
01:00:32.000 --> 01:00:48.000
Let's start with the fact that A, it's illegal right now. B, the peptide that people are buying on the internet. We're not sure what they are. Their purity, their sterility, their packaging is unknown.
01:00:49.000 --> 01:01:39.000
And while, as far as we know, there hasn't been any reports of problems related to that, there were a couple of deaths a few years ago in people who were injecting BPC-157 that weren't related to the peptide itself, but they were contaminated and people died from sepsis. So, I am strongly against using any peptide that's illegal and formulated in ways that we don't know. Let's start there. The FDA advisory panel that met a couple of weeks ago recommended that six peptides, including MOTC, would become legal to manufacture and compound under a physician's supervision with a prescription.
01:01:39.000 --> 01:02:24.000
And of course, right now, most of the people who appear to be taking MOTC don't have a real doctor involved, there's no prescription. So we're moving into a new era where this will actually be legal reasonably safe from the perspective of the material, that doesn't imply automatically that it's going to be safe long-term at any dose, but at least you know you're not going to get septic shock. And it will allow us to learn more about this. It's not something that FDA approved as a drug for any kind of specific indication, and we do not have long-term data on the safety of MOTC.
01:02:25.000 --> 01:02:42.000
Having said that, There are 250 papers published on the MOTC, well over 30 labs all over the world, mostly administering it to mouse models, and there's been no safety signals whatsoever. None.
01:02:42.000 --> 01:02:46.000
No negative issues have clearly emerged. No negative issues.
01:02:46.000 --> 01:03:31.000
And, you know, the benefits that people have shown in animal models really were typically in limited studies in three weeks, four weeks, six weeks, with the exception of one study, again, led by Dr. Lee and Dr. Reynolds, with my lab being involved in, which administered MOTC to mice three times a week for the entire length of their life, starting at middle age. And we demonstrated a 10% increase in lifespan. So I think that's compelling that at least it's unlikely to cause any kind of hidden problem in the future.
01:03:32.000 --> 01:03:59.000
We also have the opposite effect that people who don't make mochi, that 8% of the Japanese community, they seem to have at least decreased healthspan. We don't know the lifespan yet. But clearly, not having mochi isn't good. getting MOTC supplementation in mice seems to be beneficial for health men and potentially lifespan.
01:03:59.000 --> 01:04:22.000
It sounds like the main things we have are natural variants of MOTC in humans. There's one that you see in certain Japanese people. It's a non-functional or a differently functional variant, and they have problems, sarcopenia, et cetera. We know from preclinical research that using the protocols in mice and rodents with MOTC, no obvious problems emerge.
01:04:22.000 --> 01:04:39.000
Those are usually protocols where you're giving it once a day for maybe three days per week, but sometimes for many, many weeks, which for a mouse's life is quite a long time. And there's very, very limited human data for MOTC, so we don't really know much from the realm of randomized control trials.
01:04:41.000 --> 01:05:24.000
So, that's only one randomized control trial that I mentioned, which was four weeks, really small numbers, but still, it was a real study. Now, with all these peptides, there is this concept that literally hundreds of thousands of people are taking peptides now for several years, and for the most part, I don't know what people are taking. By the way, so multiple friends of mine who take peptides, including Moxie, gave me the syringes that they inject that contain Moxie, and my team measured the level
of Moxie. It's never what it's advertised to be.
01:05:24.000 --> 01:05:29.000
Really? With these, you know... questionable producers.
01:05:30.000 --> 01:05:39.000
So you guys have taken the actual MOTC that people have bought online for research purposes only, and you've tested it in your lab. Have you found contaminants? Was the potency off? What were the actual issues?
01:05:40.000 --> 01:06:06.000
Well, in my case, a syringe that was a stack, whatever that means, that included MOTC, supposedly there was zero MOTC. Wow. In another case, or two other cases, the amount of Moxie was between 20 to 80% of what was advertised. The reason for that could be A, that the manufacturers cheat, you know, there's no regulation to this.
01:06:07.000 --> 01:06:51.000
B, that the stability of the product they made because of how it was made and how it's formulated results in degradation over time. Now, there are ways to address that, but I don't know that people look to that in this illegal market that's out there. So we really can't say anything about this experience of the 1000s of people who've been taking it. But the expectation is that in the new world that we are entering, where it's going to be legal, and manufactured and compounded in certified facilities, that we will begin to collect more information.
01:06:52.000 --> 01:07:36.000
Yeah, there's no mandated way to do that. I, together with some colleagues at Stanford, are planning to start a registry for peptides, particularly MOXIE, but we'll probably try to incorporate other peptides as well. And this registry will be voluntary. HIPAA-compatible and privacy-protected, but we'll try to get as many people as possible who are using peptides, particularly MOTC, to enter their information into this large database to allow us to collect data long-term, first and foremost for safety, which by far is the most important thing.
01:07:37.000 --> 01:07:59.000
But then on What potential benefits people are seeing or not seeing and we're still developing the concept and the structure and the. online data collection tools. But I think this is going to be a very important aspect of dealing with the new reality. And as you know, there are some people who are very concerned about this.
01:08:00.000 --> 01:09:01.000
This is something that really has never happened before in this country under FDA, which is an organization with very, very strict approach to new drugs. And, you know, they are not happy with this new system, but it's here. And I think it's critical for a responsible community of physicians and scientists to do what we can to try to ensure safety, to collect data in a real way and to understand where are we going with this new universe of peptides that are legal. And most importantly for me, I consider this 503A compounding story a stepping stone toward developing newer, more potent, and fully FDA-approved versions of MOTC and other peptides.
01:09:01.000 --> 01:09:02.000
That's how I see it.
01:09:03.000 --> 01:09:28.000
I want to ask you something that's relevant to the question of formulations and stability of these things. As you mentioned, regardless of what the rules and regulations are, people are not only taking these things more and more every day, they're stacking them, as you said. And that happens in two ways, as far as I can tell. Sometimes people will take two or three separate peptides, separate syringes, and inject them, you know, one after the other.
01:09:29.000 --> 01:09:52.000
There also seem to be an increasing number of stacks that are pre-purchased. So one syringe or one vial will contain two or three peptides in the same solution. From the perspective of the peptide biochemistry and biophysics and stability, are there any concerns that you would have knowing that biology about combining multiple peptides in one solution? Could they aggregate?
01:09:52.000 --> 01:09:56.000
Could they interact and change each other? Are there any potential issues there?
01:09:57.000 --> 01:10:09.000
There are many concerns. You've named several of them right now. The bottom line is that we have no information whatsoever. My lab, at least, has never put two peptides in the same syringe.
01:10:10.000 --> 01:10:33.000
We have done experiments where we injected with two different syringes mice. with several peptides. Our key approach recently has been to combine MOTC and GLP-1 to demonstrate the benefits on muscle preservation. It's kind of a stack, if you will, and I think it's a very rational one.
01:10:34.000 --> 01:11:11.000
That does not mean that you can mix them together. Maybe there's a way to do it, but we haven't demonstrated that. It will require real chemists, which not many of them are involved in this field right now, to look at this, weigh in, and really develop the right formulation for these peptides, one by one, and potentially as stacks. I think stability in solution is a key aspect of this whole field, and it's not trivial.
01:11:11.000 --> 01:12:00.000
And I don't know that what people are using in the black market today are really stable preparations and that the stacked combinations may be problematic. I don't think there's any real evidence for serious safety concerns. But I think there's many reasons to think maybe you're not getting the fully active forms in the concentrations that you're expecting in these stacks. I think that the new era of compounded peptides is a bit of a mystery to me, whether legitimate American pharmacies will compound combination of peptides.
01:12:00.000 --> 01:12:37.000
I don't think they will. I think that the six peptides that have been recommended for compounding, which include Moxie and BPC-157, may not represent what stacks in the black market are thought to be. So I personally would argue against stacking in the same syringe for sure. We have no information about this, and it will take a lot of effort to demonstrate safety as well as stability.
01:12:38.000 --> 01:13:09.000
I
think that the conceptual use of combining two agents, one of them or two of them being peptides, is not unreasonable conceptually. And again, The GLP-1-MOTC combination makes complete sense to be explored and studied. I know there's a very popular combination of BPC-157 and TB500. There's zero publications on that combination.
01:13:10.000 --> 01:13:40.000
And indications for that are also not particularly clear. And I'm not sure that there are real benefits to stacking beyond the potential value of using a single peptide in any particular scenario. So I think that we don't have enough information to allow someone like me to comment on this other than a cautionary approach.
01:13:42.000 --> 01:14:09.000
At a high level, Does there seem to be any fundamental difference between mitochondrial peptides, those encoded in the mitochondrial genome secreted by the mitochondria versus peptides that are in the nuclear genome and that come from the nucleus? Does the fact that they come from mitochondria, that there's many mitochondria per cell and they can be located in different compartments of the cell, is there any significance to that in terms of the types of functions we see among the mitochondrial peptides compared to other peptides?
01:14:14.000 --> 01:15:01.000
Peptidome is expanding and emerging and probably has very diverse activities that we have not fully discovered. I think of this from a functional perspective, the mitochondria has several key roles, energy production, innate immunity, healthy aging, among others, protection of involvement in apoptosis. And it's particularly important biologically in the process of aging. So the nuclear genome has many, many elements that protect it from damage over time.
01:15:02.000 --> 01:15:55.000
DNA repair and other biological processes that were developed evolutionarily to protect you when you age from damage to your genes and chromosomes. The mitochondria doesn't have that, that there's no DNA repair, there's no protection, that the mitochondria really relies on eliminating damage mitochondria and making new ones. But over the process of aging, there is very clear damage and depletion and mutations in the mitochondrial genome that occur in old people. So I think that phenomena, the functionality, the potential value of mitochondrially encoded peptides is to address the fact that there are probably deficiencies that occur in older age.
01:15:56.000 --> 01:16:39.000
The nuclear microproteins, I think, will emerge as much more important in processes related to early development, cell differentiation, cellular processes that involve, you know, normal function of cells. And so far, from what I'm learning, and this is way early, and I'm not committing to this, it appears that many of the nuclear peptides and microproteins are structural. They stay inside cells. They might get incorporated into membranes inside the cell.
01:16:39.000 --> 01:17:12.000
They serve important functions. Not many of them are secreted, while at least the mitochondrial microproteins that we work on probably because I'm an endocrinologist and that's kind of what I congregate towards, but these are essentially hormones. So, if we didn't circulate this as a function, so you can think of them in the same context as you do in GLP-1 and insulin and growth hormone and other testosterone or what have you, and think of them in the context of measuring the levels with age, and showing decline and whatever.
01:17:13.000 --> 01:17:59.000
So, none of that has been done for the new class of nuclear peptides that are being discovered. And that doesn't mean that There aren't potentially nuclear peptides that could be developed as drugs, and there are several drug companies who are exploring nuclear microproteins and, you know, emerging interest in developing mitochondrial microproteins. And I'm always raising money for a new company, Nick. And if any of your listeners are interested, there's a lot of potential in developing ventures around these emerging class of molecules and pharmaceuticals.
01:17:59.000 --> 01:18:10.000
So I think this is just gonna be so many opportunities to explore in this field. And I love the way it's expanding so rapidly.
01:18:11.000 --> 01:18:49.000
Yeah, and there's definitely a lot of excitement. We might be able to talk separately offline about helping you out with some of your ventures. But as a class, a therapeutic class, when you think about peptides compared to, say, small molecule drugs, Do you think there's any fundamental differences there in terms of the types of therapies that will emerge on the peptide side as opposed to the small molecule drug side? Are these things going to be better or worse at doing certain things or come with a different risk reward profile based on the fundamental biological differences between a peptide therapy and a small molecule drug therapy?
01:18:52.000 --> 01:19:29.000
Several differences that I can think of. So first of all, the peptides we're talking about that doesn't necessarily include all of the peptides that people are using in the black market, but peptides that I work on are all naturally occurring molecules. So, in terms of safety, if I make MOTC and you make MOTC, and we live with that molecule inside our body forever, you have a reasonably good sense that it's safe within the right concentration range. So insulin, if you give somebody too much insulin, they can die from low blood sugar.
01:19:30.000 --> 01:20:07.000
But insulin in general is relatively safe. Moxie and the rest of these naturally occurring peptides at least have this guarantee that there's not going to be some crazy side effects that will kill you because it's a foreign molecule. For small molecules that are essentially designed, they're not naturally occurring, there's always the risk that there will be off-site side effect, that there will be some unexpected phenomena that's associated with that. So, I think that naturally occurring
peptides have a higher likelihood of being safe.
01:20:08.000 --> 01:20:41.000
On the other hand, people don't want to inject themselves. And, you know, when you look at GLP-1, it's a $60 billion industry that millions of Americans are enjoying the fruits of. But as soon as both Eli Lilly and Novo Nordisk came up with the oral versions, boom, people congregate to that because people don't want to inject themselves. Now, there are emerging ways to administer peptides, for example, intranasally, which might overcome the injection issue.
01:20:42.000 --> 01:21:16.000
But I think for the most part, most of the peptides will require injection. And the small molecules, of course, can be given orally. And that's the most fundamental difference that people who are looking for the benefits will consider as a decision maker. Having said that, if you look at the GLP-1 universe, The injectable peptides versus the oral versions, the peptides are much more potent.
01:21:16.000 --> 01:21:26.000
So if you look at the new oral version of a Zempik, it's less than half as potent as injected version of Zempik.
01:21:26.000 --> 01:21:27.000
Yeah, I mean, it makes sense.
01:21:27.000 --> 01:22:13.000
And also, moving from a peptide to a designed small molecule is very, very difficult, very expensive, a lot of work, and many years. So, I think that the emergence of developing peptides as drugs will rely first and foremost on maybe analogued mild modifications of these peptides, but early on keeping them as injectable peptides during the development and characterization phases. Yeah. And I also think that people are much more open today compared to 10 years ago for taking injections.
01:22:14.000 --> 01:22:26.000
Yeah, that's obviously changing. I mean, as more and more people see their mom and their sister and their brother take an injection, people become more comfortable with it. I want to ask you about designer peptides. You hinted at this earlier.
01:22:27.000 --> 01:22:46.000
There's a lot of endogenous peptides, obviously, MOTC and the other ones we talked about. And obviously it is reassuring that, hey, our bodies produce these things. So within the natural physiological range of concentrations, we know that our bodies can handle it. There's probably nothing that's gonna blow up inside of us from taking some supplemental peptides, assuming we're getting the right thing at the right dose.
01:22:47.000 --> 01:22:58.000
What about designer peptides, novel peptides that are amino acid sequences that aren't encoded in our genome and don't occur naturally? What do you see as the future there in terms of the potential risks and benefits?
01:22:59.000 --> 01:25:09.000
So, you know, there's a lot of discussions these days about how AI is going to transform drug development, or, you know, transform everything. But I think that in the field of peptides, the concept that we can now really understand structure much better, especially for large proteins, and we can try to design sequences peptides that will interact with specific binding pockets in large peptides. That's a compelling reason to employ these AI tools to try to develop completely new peptides. I think there are people already doing that at the drug development stage, and in various conditions, including cancer, where there are some undruggable proteins that are involved in cancer, where you could develop a peptide that will interact with molecules like B53 or the androgen receptor, all these large proteins involved in cancer that you target instead of with a small molecule, which sometimes just can't fit perfectly in that particular large protein, you could design completely artificial novel peptide that will fit just right and block the effect of this negative protein in cancer, for example, in metabolism or new generation. Similarly, you know, so we identified a human in analog that interacts with APOE4, but you could design a universe of peptides that could interact with APOE4 to block its effect, to prevent it from aggregating and killing cells. So all of this science relies on a really good understanding based on actual experiments and data to understand the structure of large proteins.
01:25:10.000 --> 01:25:36.000
And for that matter, also, to some degree, understanding the structure of peptides. But this is a really exciting new direction in science and drug development. There's several Nobel Prizes that have been indirectly awarded towards this area. And I think that's where you look at where the really brilliant people are going to in science today.
01:25:36.000 --> 01:26:09.000
It is an AI-driven understanding of biological processes and harnessing them for drug development. So, I think that that's the future, but it's always going to be informed by observations on natural molecules and the natural peptides, whether it's MOTC or something else, really will set the direction for designing designer peptides. So these two fields will cross talk to each other and inform each other.
01:26:09.000 --> 01:26:37.000
Yeah, yeah. I want to ask you a little bit more about diversity and variation. So I think for all of the natural endogenous peptides you've worked on that we mentioned, at least, there's natural variants that are out there, different versions and different people. What's the significance of that, both in terms of, you know, helping us think about the underlying biology here, and in thinking about how we develop treatments that might, say, work in one population but not another, or help people in different ways, and things like that?
01:26:39.000 --> 01:27:23.000
That's a great question, Nick, and I've been thinking about it a lot. So let's start with the observation that the variability in mitochondrial peptides is so much more common than the variability in nuclear genes. Much more, just because what I said about protecting cells and DNA from mutations, there's much less variation. The mutation rate in the nuclear genome is one in I
don't know how many millions of base pairs per generation, the mutation rate in the mitochondria from one generation to the next is more than 10 times higher than in the nuclear genome.
01:27:24.000 --> 01:27:56.000
So, you get a lot more diversity within the mitochondrial genome that's transferred down from mother to children and to the next generation, and many of these are random. And they might be found in a person, and if that particular variant has no positive value, it will disappear. But if somebody, so we have several gain-of-function variants that we identified. One is the UMP3S.
01:27:57.000 --> 01:28:29.000
Another is a SHLEP2, which is another peptide we discovered some years ago. There's a SHLEP2 gain-of-function mutation that protects from Parkinson's disease. And there might be, there appear to be other Gamma-function mutations that enhance the function of peptides. Then there's all the negative loss-of-function mutations, like in MOTC and SHMOOZ and MENSH, again, that reduce the activity, which might be a good thing in certain situations.
01:28:30.000 --> 01:29:07.000
So, first and foremost, there's a lot of diversity in these peptides in human beings, which is ethnospecific. And that certainly facilitates discovery. So, if it wasn't for our, you know, the Hispanic or the Mexican-American population that we studied, we never would have discovered dementia mutation. That way we have, the question that you're leading me to is, should MENSH, for example, be considered a precision medicine approach for Hispanic Americans with diabetes?
01:29:08.000 --> 01:29:55.000
or could it be universally used potentially as a drug for all people with diabetes? We don't know yet, but the bottom line is that if you look at MOTC, it is deficient in 8% of Japanese. We don't know, I don't think there's a lot of peptide use in Japan right now, and I'm not familiar with any Japanese Americans who reported any benefits who are genotypes. Theoretically, I would love to see at some point a targeted clinical trial comparing people of Japanese extraction with and without the MOTC mutation treated with MOTC to see if they benefit more because they don't make their own.
01:29:56.000 --> 01:30:45.000
But I think that there's generally a well-accepted concept that even if you don't have a mutation in MOTC or MENSH or what have you, you can benefit from exogenous administration of this peptide, just like you do with insulin and GLP-1 and all of those. So the potential for precision medicine approach based on this is exciting, not been proven yet. the generability of any particular peptide that was discovered by the fact that there is a population with a deficiency that exhibits a disease state. may or may not limit the development of such a peptide in a similar conditions with people who don't have a deficiency.
01:30:46.000 --> 01:31:13.000
But the bottom line is, the other thing that's happening in modern medicine is the concept that everything is moving toward
a precision approach. And that certainly diagnostically is important, targeting particular interventions to people with particular genetic structures that might benefit from that. It's compelling. It's already happening in certain areas in medicine.
01:31:15.000 --> 01:31:27.000
It has not yet been applied in the peptide world. I hope that we will get to a place that we have the capacity to scientifically demonstrate the value of that, but it hasn't happened yet.
01:31:29.000 --> 01:31:39.000
What are one or two of the things you're working on in the lab today to do with peptide biology that you think are going to give us some exciting insights in the next, say, one to two years? What's coming next?
01:31:41.000 --> 01:32:29.000
So without spilling the beans on secret projects that my students have that are going to make their careers and I don't want to steal their thunder, and there are a bunch of interesting things going on, I am beyond the fact that MOTSE is going to be legal in a few months, and there's a lot of possibilities there to explore its utility in muscle preservation. The peptide that I'm most excited about at the moment, beyond that, is schmooze. Schmooze is effective in animal models to reduce the development of cognitive decline and Alzheimer's symptoms.
01:32:30.000 --> 01:33:01.000
We are successfully administering schmooze in mice intranasally, which is sort of the emerging tool in the field. And I think that That is the peptide I hope will get more attention. Maybe we can secure funding to develop it into a drug. But I think that that is where I think a lot of the new discoveries that are not yet published are happening in our lab.
01:33:01.000 --> 01:33:58.000
We now linked schmooze remarkably, not just to Alzheimer's disease, but to lung disease. Who knew, just some collaborator of mine who's into the lung, physician did the screen, the genetic screen, and lo and behold, Shmue's mutation might be related to lung disease and provides an opportunity for intervention there. We're also looking at new disease states and new cohorts where we hope to discover new peptides. I think I always start with normal physiology, so energy and metabolism is the main goal of mitochondrial function, and several of the peptides work on that, motzy, mensch, perhaps humanin.
01:34:00.000 --> 01:34:40.000
Immunity, innate immunity, is important, is an important part of mitochondrial function. We're now discovering new peptides involving immunity, one that was just published this week, is called Muzzle, and it's been discovered by one of my former students, Donna Silverstein, who was interested in immunity, and she did a screen, instead of diabetes or Alzheimer's, for abnormal immune markers, like IL-1 and IL-6. Of course, elevated IL-1 indicates inflammation.
01:34:40.000 --> 01:34:58.000
It's not good. It's associated with unhealthy aging and disease. So she discovered a mutation in this new muzzle peptide that's associated with elevated IL-1 and IL-6. And that paper was also just published.
01:34:58.000 --> 01:35:38.000
And the potential of intervening in immune or inflammation situations is very exciting as well. But I like to drive the discovery by thinking back, what is the mitochondria really doing, and how potentially could mitochondrial microproteins be involved in that? And I also am a big believer that the most important thing for healthy aging, Nick, is lifestyle. diet, exercise, stress reduction, avoiding inflammation, and so on.
01:35:39.000 --> 01:35:49.000
And by using those guidelines to try to discover new mitochondrial microproteins, I think you're going to get the biggest bunk for your back.
01:35:51.000 --> 01:36:10.000
Very briefly, we know that endogenous mitochondrial peptides like MOTC are modulated by exercise. We can exercise and affect how much MOTC is produced by our mitochondria. Is there any evidence that other lifestyle factors like diet or dietary components of various kinds affect MOTC or other mitochondrial proteins?
01:36:10.000 --> 01:36:45.000
Yes, so exactly the point that I'm leading to. We do believe that diet regulates...we know diet regulates mitochondria for sure, but humanin is induced by certain diets, as do other peptides, but we just published a paper on Mediterranean diets. Now, again, I come from a Mediterranean extraction. I don't know about you, but the Mediterranean diet is the one diet that has definitively been associated with healthy aging.
01:36:46.000 --> 01:36:48.000
And define that for us so people know concretely what that means.
01:36:49.000 --> 01:37:45.000
So the Mediterranean diet is based on unprocessed food, limited carbs, a lot of fish, a lot of vegetables and fruits, and has been eaten in the Mediterranean for many centuries. And people who eat Mediterranean diet are much more likely to age well and have longevity compared to people who don't. And my colleague, Roberto Di Sinanza, who is a big expert on Mediterranean diet, has shown, like many other investigators, the benefits of Mediterranean diet, particularly comparing people who adhere to Mediterranean diet versus those who don't in Italy, where that's like one of the birthplaces of the diet. And he's shown that if you adhere to Mediterranean diet, there's a lot of things that look better on your blood tests.
01:37:46.000 --> 01:38:23.000
We then took a whole bunch of people that either adhere or don't adhere to Mediterranean diet, measured monoclonal peptides, and shown that both human and particularly schmooze are much higher in people who eat the Mediterranean diet, and specifically olive oil, and I'm a big olive oil guy, olive oil increases schmooze levels substantially, not in an intervention trial, but in an observational trial. So we hope to find ways to demonstrate what specific foods elevate which peptides that is related to health. Wow.
01:38:23.000 --> 01:38:29.000
Well, yeah, one of my grandparents was Greek, so I've been eating olives all my life. So
hopefully that's good news for me.
01:38:30.000 --> 01:38:56.000
Absolutely. And the Greece is also where many of the research studies on Mediterranean diets originate. But that brings me to a point you alluded to earlier. which is, if you're from the Mediterranean, Greece, Italy, Spain, Israel, whatever, and you're eating Mediterranean diet, there's a very good chance you're doing something good for yourself.
01:38:57.000 --> 01:39:17.000
But what if you're Swedish, or Chinese, or from Nigeria? Is there evidence that a Mediterranean diet is really better for you then? It's not entirely clear. And for example, in Sweden, somebody did a study on the Mediterranean diet, couldn't show any benefits.
01:39:17.000 --> 01:39:43.000
But the Nordic countries actually have a healthy diet, sometimes referred to as the Nordic diet. A lot of fish, you know, whole grain stuff. I'm not an expert, but that diet has been shown to be beneficial in that part of the world. We know that in Asia, where many people have longevity, they eat very certain diets that are quite different.
01:39:43.000 --> 01:40:11.000
So the whole blue zone field, which you probably have heard of, was trying to find what are the similarities between all these very different places? What are the habits and the foods that they all share? And it's a limited number of things. So, I think that it's very likely that people from different ethnicities might benefit from slightly different modalities of diet and exercise.
01:40:11.000 --> 01:40:47.000
And similarly, might have different profiles of peptides in their blood and potentially might benefit from different types of interventions with pharmaceuticals based on peptides. And for example, GLP-1, the peptides that is the ultimate stars of the field, different ethnicities respond differently. And the fact of the matter is that almost every drug that's being developed until now, has been developed for a European audience. That's where most of the studies are done.
01:40:47.000 --> 01:41:03.000
That's how they're tested. And after they're approved and demonstrated to be effective in white people, then they're tested in other races. And in many other ethnicities, GOP1 is not as effective as it is in Europeans.
01:41:04.000 --> 01:41:05.000
Really? What are examples?
01:41:06.000 --> 01:41:20.000
You know, I think that both Hispanics and Asians show a 20 or 30% lesser response to GLP-1. They still respond, don't get me wrong, but if you just look at percent weight loss.
01:41:20.000 --> 01:41:22.000
Yeah, the magnitude is less in those populations.
01:41:22.000 --> 01:41:47.000
It's less in those populations, which could be explained by different biological subtle differences between these two, between these different populations. There might be a way to understand that and develop interventions specifically to those types of people. And you don't have to say, if you're white, you get this, if you're black, you get that. Especially, by the way, in this country.
01:41:49.000 --> 01:42:09.000
The admixture is everywhere. There's so much intermarriage. So you could be classifying yourself as Greek, but you might have some Asian grandfather that determines your susceptibility to disease and response. So doing a genetic analysis, don't call it ethnicity.
01:42:09.000 --> 01:42:35.000
Just get a gene sequencing thing, 23 million, what have you. And based on that information, say you should go on a GOP1, or you should go on Metformin to address your issues with metabolism and diabetes. So this precision medicine approach, we've been talking about it for a couple of decades. It hasn't quite reached this very practical level, but it's coming there.
01:42:35.000 --> 01:42:36.000
It's coming. Yeah.
01:42:36.000 --> 01:42:37.000
Not bad.
01:42:38.000 --> 01:42:43.000
Any final thoughts or things you want to reiterate from our discussion as it relates to peptides and the research you've done?
01:42:45.000 --> 01:43:02.000
So first, I always want to install a level of caution in people. There's a lot of enthusiasm about peptides, but at the same time, there's so much we don't know. Everything that's out there right now is illegal and unproven. So let's start there.
01:43:03.000 --> 01:44:21.000
But now when some peptides are going to be legal to prescribe, I hope that a responsible community of physicians will oversee this and will try to limit whatever use of these peptides might happen to sensible, safe indications, and that the community of physicians and prescribers and healthcare professionals will try to incorporate whatever peptide use is going to happen into what we're doing already with people's health, and particularly the concept of registries and data collection and some clinical trials that can be developed will teach us a lot more about how to use these substances safely, and hopefully there'll be an investment and an interest from pharma in taking some of these to the next step, developing high-potency versions. Now, if you look at GLP-1, the first one was produced and marketed twenty years ago with minimally effective the next one, five or ten years later with more more effective fifteen years later was even more effective.
01:44:22.000 --> 01:44:49.000
A few years ago, Munjaro is even more effective, and soon, retatratide is super effective. So, the evolution of these analogs can be replicated for other peptides, like MOTC, where we are already in our lab developing new analogs that are more potent. So, I think that this is not going to be a static field. It's always going to be improvements, better versions, better ways to use it.
01:44:50.000 --> 01:44:57.000
And I hope that we'll all do it responsibly. I think I'd like to finish there.
01:44:57.000 --> 01:45:03.000
All right. Well, Professor Hasse Cohen, thank you very much for your time. I really enjoyed this. I've been following your work for a little while now.
01:45:04.000 --> 01:45:09.000
So there's a lot to follow. This field is really blowing up. But yeah, thank you very much for your time.
01:45:10.000 --> 01:45:10.000
My pleasure.
01:45:20.000 --> 01:45:47.000
A great way to support my efforts is to visit my support page at mindandmatter.substack.com. A link to that page is in the episode description, or you can search for it on the Substack page itself. The support page has an up-to-date list of my affiliate partners. These are companies I work with, and if you buy those products through those links or using the discount codes provided, those will get you a great deal on a variety of products related to optimizing physical, metabolic, or mental health and vitality.
01:45:47.000 --> 01:46:15.000
These are all products I use myself, and some of them are directly related to podcast episodes or formulated by Mind & Matter guests. For example, there's a great product called Keto Citra formulated by a kidney biologist who is on episode number 186. It contains the ketone body BHB together with several minerals in a precise ratio formulated with kidney health in mind. There are also links to products like physical technology devices to track your metabolic health, digital applications to help you find and learn about food and consumer products, and more.
01:46:16.000 --> 01:46:34.000
One product I use every day is the AquaTrue water filter. I recommend this to everyone because it gets everything out of your drinking water, heavy metals, microbes, endocrine disruptors, microplastics, you name it. Other charcoal or gravity-based filters that a lot of people use don't get everything out, they just get some of the stuff out. So I really like the AquaTrue product.
01:46:34.000 --> 01:46:44.000
You can look for a link to my affiliate partners on my support page or directly in the episode description to this episode, or you can go to mindandmatter.substack.com to find it there.